-
JEM: The development of a new mouse model may be the key to developing better HIV therapies
Time of Update: 2021-06-23
Related research results were recently published in the Journal of Experimental Medicine, with the title of the paper "A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies" .
-
Renfu Class 1 New Drug Propofol Disodium for Injection Approved for Marketing
Time of Update: 2021-06-23
On May 24, the official website of NMPA showed that Renfu’s Class 1 new drug, propofol disodium for injection, was approved for marketing, and the indication was general anesthesia induction .
-
A pharmaceutical company was fined 3 million in the batch number change!
Time of Update: 2021-06-23
The C12012063 batch of poppy husk production ingredients audit form NO: 202012063 has no regulations on the mixing ratio of ingredients and does not comply with the "Drug Production Quality Management" Standardize (Revised in 2010)" Appendix "Chinese Medicine Decoction Pieces" Article 43 (2) and (4) requirements .
-
Trilaciclib introduced by Simcere has been approved for clinical use
Time of Update: 2021-06-22
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Trilaciclib for injection, jointly declared by Simcere and G1 Therapeutics, has obtained an implied license for a clinical trial to prescribe the treatment of triple-negative breast cancer .
-
Jingxin Pharmaceutical Memantine Hydrochloride Sustained Release Capsules Obtained Drug Registration Approval
Time of Update: 2021-06-22
On June 15, Jingxin Pharmaceutical announced that it had recently received the "Drug Registration Certificate" for the chemical drug "Memantine Hydrochloride Sustained Release Capsules" [Specification 28mg] approved and issued by the State Food and Drug Administration .
-
Shouxiangu: Gynecological Shiwei Tablets Received Drug Re-registration Approval Notice
Time of Update: 2021-06-22
Since this product has not been produced for a long time, when production is resumed, an application for on-site inspection must be submitted to the Zhejiang Food and Drug Administration.
After on-site inspection and random inspection of a batch of products, it can be marketed .
-
Chen Jiafu, deputy general manager of Tongrentang, resigns
Time of Update: 2021-06-22
Chen Jiafu .
Chen Jiafu ceased to be the deputy general manager of the company due to job changes and applied to resign from the position of deputy general manager of the company .
-
Ascent Pharma's Bcl-2 inhibitor APG-2575 obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-06-22
The study is a global multi-center, open, phase Ib/II clinical study, which aims to evaluate the progress of APG-2575 monotherapy in patients with advanced solid tumors, or in combination with CDK4/6 inhibitor palbociclib after treatment with CDK4/6 inhibitors.
-
The number of pharmaceutical representatives of 30 Japanese companies ranks in 2021, the number of pharmaceutical representatives continues to decrease
Time of Update: 2021-06-22
Of course, in the past year, there have been companies that have increased the number of medical representatives, but they are basically more than 20 people, such as Xinglin Pharmaceutical, Otsuka Pharmaceutical, and Towa Pharmaceuticals.
-
Puri Pharmaceuticals Pantoprazole Sodium for Injection Receives Health Canada Approval
Time of Update: 2021-06-22
Pantoprazole Sodium for Injection is a selective long-acting proton pump inhibitor .
It is relatively stable under neutral and weak acidic conditions, and is rapidly activated under strong acidic conditions, thereby having better selectivity for H+ and K+-ATPase .
-
China Resources Shuanghe Irbesartan Dispersible Tablets were the first to pass the quality and efficacy evaluation of generic drugs
Time of Update: 2021-06-22
Combining medical and urban retail data, Shuanghe Limin irbesartan dispersible tablets accounted for 3.
-
KRAS inhibitor!
Time of Update: 2021-06-22
According to the press release, Jacos Pharmaceuticals will start multi-center clinical trials for tumor patients with non-small cell lung cancer, colorectal cancer and other solid tumors in China and the United States, and plan to start patient enrollment in the second half of 2021 .
-
Kangtai Bio freeze-dried Haemophilus influenzae type b conjugate vaccine obtained drug registration certificate
Time of Update: 2021-06-22
(hereinafter referred to as "Minhai Biological"), had recently received the "Drug Registration Certificate" issued by the State Drug Administration .
The freeze-dried Haemophilus influenzae type b conjugate vaccine is suitable for children from 2 months old to 5 years old.
-
14 over 100 million proprietary Chinese medicine plasters exposed!
Time of Update: 2021-06-22
According to data from Meinenet, the market share of terminal pain relief plasters in physical pharmacies in Chinese cities has maintained steady growth in recent years, with sales exceeding 600 million yuan in 2020 .
-
Yourui Medicine Obtains the Development and Commercialization Rights of VeronaCOPD New Drug in Greater China
Time of Update: 2021-06-22
According to the terms of the agreement, Verona has granted Yourui Medicine the exclusive right to clinical development and commercialization of ensifentrine in Greater China .
Note: The original text has been deletedReference materials:[1] Verona Pharma and Yourui Pharmaceutical announced a strategic cooperation of US$219 million to develop and commercialize Ensifentrine in Greater China.
-
Is prescription drug retail a good business?
Time of Update: 2021-06-22
Therefore, although small chain and individual pharmacies still have a certain market share, the prescription drug retail market is ultimately concentrated in the hands of a few large pharmacies and PBMs .
-
2 billion large varieties!
Time of Update: 2021-06-22
Sales of terminal lansoprazole injections in public medical institutions in China (unit: ten thousand yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternPreviously reviewed companies for Lansoprazole for injectionSource: Mi Nei Net Consistency Evaluation DatabaseLansoprazole injection has been included in the fifth batch of centralized procurement, and the bid will be opened on June 23.
-
2020 Medical Insurance Statistics Bulletin released!
Time of Update: 2021-06-22
In 2019, the National Medical Insurance Bureau bulletin showed that the hospitalization expense fund within the scope of the employee medical insurance policy paid 85.
In 2019, the National Medical Insurance Bureau bulletin showed that the hospitalization expense fund within the scope of the employee medical insurance policy paid 85.
-
Zhang Jinjun, deputy general manager of Qianke Biology, resigns
Time of Update: 2021-06-22
According to the announcement, the company’s board of directors recently received a written resignation report from the company’s deputy general manager Zhang Jinjun .
Zhang Jinjun applied to resign from the position of deputy general manager of the company due to personal reasons .
-
Jingfeng Pharmaceutical Letrozole Tablets Obtained Drug Registration Approval
Time of Update: 2021-06-22
It is reported that letrozole is a selective, non-steroidal aromatase inhibitor, which has no negative effects on the secretion of glucocorticoids and mineralocorticoids and thyroid function .
It is also suitable for the treatment of postmenopausal, estrogen receptor-positive, progesterone-receptor-positive, or advanced breast cancer patients whose receptor status is unknown.
